The value of time savings in breast cancer therapy for patients and healthcare providers: the subcutaneous injection of pertuzumab and trastuzumab fixed-dose combination at a tertiary care center in the UAE
{{output}}
Aim: To measure time saving associated with the subcutaneous (SC) fixed-dose combination of pertuzumab and trastuzumab (PH FDC SC) compared with intravenous (IV) pertuzumab and trastuzumab in patients with HER2-positive breast cancer. Materials & methods: This... ...
